Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.34 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.34 |
| ▸ | CHRNG | P07510 | 1/20 | 0.34 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.34 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRND | Q07001 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6098615 | 0.87 | CHRNB2 (0.36) | SLC6A3SLC6A4GRM5CHRNB2CHRNA4 | |
| SCHEMBL6099971 | 0.86 | SLC6A3 (0.38) | SLC6A3SLC6A4GRM5CHRNB2CHRNA4 | |
| SCHEMBL6099874 | 0.85 | XPO1 (0.37) | SLC6A3SLC6A4GRM5CHRNB2CHRNA4 | |
| SCHEMBL6099966 | 0.84 | SCN9A (0.38) | SLC6A3SLC6A4CHRNB2CHRNA4SLC6A2 | |
| SCHEMBL6099580 | 0.83 | CTSA (0.42) | SLC6A3SLC6A4CHRNB2CHRNA4SLC6A2 | |
| SCHEMBL6099707 | 0.82 | SLC6A3 (0.38) | SLC6A3SLC6A4GRM5CHRNB2CHRNA4 | |
| SCHEMBL6101273 | 0.81 | SLC6A4 (0.42) | SLC6A3SLC6A4CHRNB2CHRNA4CHRNA1 | |
| SCHEMBL6101339 | 0.81 | SCN9A (0.37) | SLC6A3SLC6A4GRM5CHRNB2CHRNA4 | |
| SCHEMBL6101623 | 0.80 | CHRNB2 (0.34) | CHRNB2CHRNA4CHRNA1CHRNGCHRNB1 | |
| SCHEMBL6098147 | 0.79 | SCN9A (0.38) | SLC6A3CHRNB2CHRNA4SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | claimed |
| US-7001900-B2 | Azabicyclic compounds for the treatment of disease | PFIZER INC. (US) | 2006-02-21 | — | — | US | disclosed |
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | MALT1, TPMT, CYP2B6 | SLC6A3 1166/4885SLC6A4 2113/4885GRM5 1965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.